REG - Oxford Biomedica PLC - 2022 Preliminary results revised date

Oxford BioMedicaAnnouncement

19/04/2023 18:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS8234Wa&default-theme=true

RNS Number : 8234W  Oxford Biomedica PLC  19 April 2023

 

2022 preliminary results revised date, guidance unchanged

 

Oxford, UK - 19 April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO,
today announces a revised date for the publication of its preliminary results
for the year ended 31 December 2022.

 

The Company's auditor, KPMG LLP, has requested additional time to complete its
standard procedures due to the increased scope of the expanded business.

 

As a result, the Company will now announce its results on Tuesday 25 April
2023, a delay to the previously planned date of 20 April 2023.

 

Oxford Biomedica reiterates guidance given at the time of its interim results
and confirms that the change of results date has not arisen as a result of any
concerns relating to the 2022 financial results or the future outlook of the
Company.

 

 

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Taylor Boyd, VP, Head of IR - T: +1 919 539 1234 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in gene and cell therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGMDNLZGFZM